Results of Share Purchase Plan
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Paradigm Biopharmaceuticals Ltd. has announced the results of its oversubscribed Share Purchase Plan, which raised significant funds from existing shareholders. The total capital raised, including a recent placement, amounts to a substantial figure that enhances the company's financial position as it progresses in clinical trials. Settlement and allotment of shares from the Share Purchase Plan are expected to occur shortly, with trading commencing soon after.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- DSMB 20% Review Supports Phase 3, Moldova Activated
- March 2026 Quarterly Activities Report & Appendix 4C
- Upsized $14M Placement Extends Runway Post IA
- Paradigm Achieves 50% Patient Dosing in Phase 3
- Appendix 4D and Half Year Report
Later from Paradigm Biopharmaceuticals
- PAR Completes Enrolment in Pivotal Phase 3
- Drawdown of Tranche 4 under the Convertible Note Facility
- Paradigm Receives $5.75m R&D Tax Incentive Refund
- June 2026 Quarterly Activities Report & Appendix 4C
- Appendix 4E and 2026 Annual Report
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals